Thiopurine methyltransferase: a review and a clinical pilot study.

  • Keuzenkamp-Jansen C
  • Leegwater P
  • De Abreu R
 et al. 
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Thiopurine methyltransferase (TPMT) is an important enzyme in the metabolism of 6-mercaptopurine (6MP), which is used in the treatment of acute lymphoblastic leukemia (ALL). TPMT catalyzes the formation of methylthioinosine monophosphate (MetIMP), which is cytotoxic for cultured cell lines, and it plays a role in detoxification of 6MP. Population studies show a genetic polymorphism for TPMT with both high and low activity alleles. About 1 of 300 subjects is homozygous for the low activity. The function TPMT plays in detoxification or therapeutic efficacy of 6MP in vivo is not clear. In this article the genetic polymorphism of TPMT is reviewed and the contribution of TPMT to the cytotoxic action, or detoxification, of 6MP in children with ALL is discussed. Induction of TPMT activity has been described during the treatment for ALL. We performed a pilot study on the influence of high-dose 6MP infusions (1300 mg/m2 in 24 h) on TPMT activity of peripheral blood mononuclear cells (pMNC) of eleven patients with ALL. The TPMT activities were in, or, above the normal range. There was no statistically significant difference between the TPMT activities before and after the 6MP infusions. MetIMP levels in pMNC increased during successive courses. This might be explained by TPMT induction, but other explanations are plausible as well. Twenty five percent of the TPMT assays failed, because less than the necessary 5.10(6) pMNC could be isolated from the blood of leukopenic patients. Red blood cells can not be used for TPMT measurements, since transfusions are frequently required during the treatment with 6MP infusions. Therefore, the influence of high-dose 6MP infusions on TPMT activity can only be investigated further when a TPMT assay which requires less pMNC has been developed.

Author-supplied keywords

  • 6-Mercaptopurine
  • 6-Mercaptopurine: metabolism
  • 6-Mercaptopurine: pharmacokinetics
  • 6-Mercaptopurine: therapeutic use
  • Antimetabolites, Antineoplastic
  • Antimetabolites, Antineoplastic: metabolism
  • Antimetabolites, Antineoplastic: pharmacokinetics
  • Antimetabolites, Antineoplastic: therapeutic use
  • Humans
  • Metabolic Detoxication, Drug
  • Methyltransferases
  • Methyltransferases: genetics
  • Methyltransferases: metabolism
  • Pilot Projects
  • Polymorphism, Genetic
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma: dr
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma: me

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • C W Keuzenkamp-Jansen

  • P a Leegwater

  • R a De Abreu

  • M a Lambooy

  • J P Bokkerink

  • J M Trijbels

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free